Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Aguiar PN Jr, Haaland B, Park W, San Tan P, Del Giglio A, …

JAMA Oncology 4(8), 1080–1084